Design Therapeutics, Inc. (NASDAQ: DSGN) is a Healthcare company (Biotechnology) with a market capitalization of $630M. The Maz Rating grades it against the other companies in its sector.
Design Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.84, Design Therapeutics, Inc. trades at 3.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -35.5%, return on invested capital of -40.2% and a free cash flow yield of -9.4%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 16.78. Over the past 52 weeks the share price ranged from $7.25 to $17.25, with a beta of 1.74.
Design Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 4 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.